« Back to Record
Citation APA

de Azambuja, E., Zardavas, D., Lemort, M., Rossari, J., Moulin, C., Buttice, A., D'Hondt, V., Lebrun, F., Lalami, Y., Cardoso, F., Sotiriou, C., Gil, T., Devriendt, D., Paesmans, M., Piccart-Gebhart, M., & Awada, A. (2013). Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trial. Annals of oncology, 24(12), 2985-2989. doi:10.1093/annonc/mdt359


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/157834

de Azambuja, E., Zardavas, D., Lemort, M., Rossari, J., Moulin, C., Buttice, A., D'Hondt, V., Lebrun, F., Lalami, Y., Cardoso, F., Sotiriou, C., Gil, T., Devriendt, D., Paesmans, M., Piccart-Gebhart, M., & Awada, A. (2013). Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trial. Annals of oncology, 24(12), 2985-2989. doi:10.1093/annonc/mdt359